Cambridge, Mass. — Enveric Biosciences said newly finalized U.S. Food and Drug Administration guidance for psychedelic drug development highlights regulatory and clinical challenges that its non-hallucinogenic drug candidate EB-003 is designed to address.
The guidance covers clinical investigations of psychedelic and psychedelic-inspired therapies, including concerns related to trial blinding, patient monitoring, abuse potential, repeat dosing and the role of psychotherapy.
“The final guidance reflects the FDA’s continued engagement with clinical development issues in this field and underscores the importance of generating data that can support rigorous regulatory review,” said Joseph Tucker, Ph.D., CEO of Enveric.
“The agency is not lowering the standard. It is giving developers a clearer view of the issues that must be solved, including functional unblinding, patient monitoring, abuse potential, repeat dosing, and the role of psychotherapy. Those are exactly the types of issues that informed how we designed EB-003,” he added.
EB-003 is being developed to activate neuroplasticity-related receptor signaling associated with classic psychedelics without producing a hallucinogenic experience.
Enveric said that profile, if confirmed in clinical trials, could allow EB-003 to be studied using more conventional blinded trial designs and potentially support a simpler outpatient treatment model.
The company noted that perceptual effects associated with psychedelic drugs can reveal whether a patient received the active treatment, making clinical trial blinding more difficult. Psychedelic therapies may also require extended observation by trained personnel and can complicate efforts to distinguish the effects of the drug from those of accompanying psychotherapy.
“Many of the hardest development and commercial problems in this field are not necessarily created by the therapeutic target,” Tucker said. “They are created by the hallucinogenic experience.”
“That experience can make blinding difficult, require hours of supervision, confound the effects of the drug with those of psychotherapy, and create questions around abuse potential. If clinical studies confirm the non-hallucinogenic profile observed in preclinical models, we believe EB-003 clinical development will be less challenging and yield more clear data readouts, and a more practical treatment model,” he added.
The FDA guidance also encourages drug developers to engage with the agency early and discusses the potential use of computer modeling and other new testing approaches to help evaluate safety and abuse potential.
Enveric said those methods could be particularly relevant to purpose-designed compounds such as EB-003 because their receptor activity, off-target effects and potential to produce hallucinogenic-like responses can be evaluated during development.
The FDA also announced a Sept. 14 public hearing on the possible future use of psychedelic therapies in supervised and supportive settings. The hearing is expected to address provider training, patient monitoring, reimbursement, access and treatment-center capacity.
“The September hearing is not an advisory committee review of a particular drug,” Tucker said. “Rather the FDA is raising practical questions about the infrastructure that would be needed to deliver supervised psychedelic treatments safely and broadly.”
Enveric’s planned Phase 1 clinical program for EB-003 will evaluate safety, tolerability, pharmacokinetics, subjective effects and pharmacodynamic biomarkers following single and repeat doses.
Later studies in patients would assess efficacy, durability of treatment effects and the dosing schedule needed to maintain a therapeutic benefit.
